Kindred Biosciences, Inc. (KIN) Q3 2019 Earnings Conference Call November 12, 2019 4:30 PM ET
Company Participants
Richard Chin - Founder and Chief Executive Officer
Wendy Wee - Chief Financial Officer
Denise Bevers - Founder, President and Chief Operating Officer
Conference Call Participants
Brandon Folkes - Cantor Fitzgerald
Balaji Prasad - Barclays
Nathan Weinstein - Aegis Capital
Swayampakula Ramakanth - HC Wainwright
Brooks O'Neil - Lake Street Capital
Ben Haynor - Alliance Global Partners
Operator
Welcome to the Third Quarter 2019 Financial Results Conference Call and Webcast for Kindred Biosciences. At this time, all participants have in placed in a listen-only mode. At the end of the prepared statements, participants will have the opportunity to ask questions. [Operator Instructions] Please be advised that today's conference is being recorded.
Please note that the remarks today will include forward-looking statements and that actual results could differ materially from those projected or implied in forward-looking statements. For a description of important factors that could cause actual results to differ, we refer you to the forward-looking statements in today's press release and the note on forward-looking statements in the company's SEC filings.
It is now my pleasure to turn the call over to Kindred Bio's, CEO, Richard Chin, Dr. Chin. Please proceed.
Richard Chin
Thank you, operator. Good afternoon and welcome to our third quarter 2019 financial results call. Joining me today from the management team of Kindred Bio are Denise Bevers, our President and COO; Wendy Wee, our CFO; and Katja Buhrer, our VP of Corporate Development and Investor Relations.
As we stated in our press release, our revenue was $1.1 million in the third quarter, while this is lower than we expected. I should note that quarterly revenues reflect ongoing variability in the distributor ordering patterns, which are the norm in industry.
- Read more current ELAN analysis and news
- View all earnings call transcripts